ADVERTISEMENT

Speculative buy on Bluebird Bio (BLUE)...

njfan47

Well-Known Member
Jan 8, 2009
3,337
41
48
This company is using gene therapy treatment, rather than the traditional chemotherapy and radiation to treat cancer. Currently, they are working with Celgene in a Phase 1 clinical study, so it's very early, but they are clearly onto something. The stock is not cheap at $106, and is for speculative accounts only, at this time, but it could be a big winner and takeover candidate.
 
Bluebird Bio was up $12 today to $125, so we've got an 18% gain in two months. No specific news on the company, but another company who develops CAR-T (chimeric antigen receptor t-cell) therapies, Novartis, had its therapy approved by the FDA earlier this week.

Both companies are still working to develop a drug to treat Trump Derangement Syndrome, although several professionals have recommended counseling instead. Others hope that the deranged liberals don't get either counseling or a drug, as the entertainment value on this board might disappear.
 
Bluebird Bio (BLUE) is now up to $165. Stock is up 55% in the 5+ months since the original recommendation. Continue to hold the stock. I hope samuel and reluctant didn't buy the stock. In fact, I'd be shocked if they did.
 
Don't you love this Bull Market. Even Democrats can make money in this market,. That was a joke guys.
 
Bluebird Bio is up $40 today to $211. While the 23% one-day gain makes it tempting to take profits, it's best to still hold on. A phase one trial of Bluebird's CAR-T drug (bb2121) was effective on 17 of 18 patients who had advanced multiple myeloma, a blood cancer. Seven of the patients were considered to have been complete responders, meaning that all signs of cancer disappeared.

Bluebird could be a very good takeover candidate; the leading suitor might be its partner in bb2121, Celgene. With Bluebird having a current market cap of $10 billion, maybe $15 billion in a takeover, $85 billion Celgene could be in a position to do the deal, but maybe Pfizer or Merck get involved too.
 
Bluebird Bio corrected today, closing at $190.95. At this level, it's a buy, but with the understanding that the above-mentioned testing is phase one of the three that are needed in order to achieve commercialization.
 
Not to monopolize the board with Bluebird, but the latest news is that they are going to do a secondary stock offering of 3.2 million shares at $185. That has pushed the price down to a low of $181 this morning and $182 right now. This dilutes potential earnings, but it's not a big issue. And, on the positive side, it gives the company more working capital. Buy more.
 
Update: Bluebird has bounced back to $213 as of today. Liberals on this board think the market is crashing (talk about delusional), but stocks like Bluebird continue to move forward and is now up 100% from the recommendation made in late June 2017. We know that Sammy didn't buy because he's "not in the stock market."
 
Bluebird Bio closed at $231.95 on Friday, up $6.00 vs. Thursday's close. Continue to hold in spite of 119% gain in nine months. There could still be a takeover although the company now has a market capitalization of $11.6 billion, so it would be a lot to take on.
 
ADVERTISEMENT
ADVERTISEMENT